Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.06
MNK's Cash-to-Debt is ranked lower than
94% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. MNK: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
MNK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.19 Max: N/A
Current: 0.06
Equity-to-Asset 0.33
MNK's Equity-to-Asset is ranked lower than
85% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. MNK: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
MNK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.34 Max: 0.41
Current: 0.33
0.25
0.41
Interest Coverage 0.61
MNK's Interest Coverage is ranked lower than
98% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.12 vs. MNK: 0.61 )
Ranked among companies with meaningful Interest Coverage only.
MNK' s Interest Coverage Range Over the Past 10 Years
Min: 0.53  Med: 2.69 Max: 470.4
Current: 0.61
0.53
470.4
Piotroski F-Score: 5
Altman Z-Score: 0.62
Beneish M-Score: -2.81
WACC vs ROIC
14.10%
3.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 7.01
MNK's Operating Margin % is ranked lower than
53% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. MNK: 7.01 )
Ranked among companies with meaningful Operating Margin % only.
MNK' s Operating Margin % Range Over the Past 10 Years
Min: 2.63  Med: 11.68 Max: 18.26
Current: 7.01
2.63
18.26
Net Margin % 8.48
MNK's Net Margin % is ranked higher than
59% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MNK: 8.48 )
Ranked among companies with meaningful Net Margin % only.
MNK' s Net Margin % Range Over the Past 10 Years
Min: -19.35  Med: 7 Max: 19.04
Current: 8.48
-19.35
19.04
ROE % 5.42
MNK's ROE % is ranked lower than
55% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. MNK: 5.42 )
Ranked among companies with meaningful ROE % only.
MNK' s ROE % Range Over the Past 10 Years
Min: -10.28  Med: 7.85 Max: 12.17
Current: 5.42
-10.28
12.17
ROA % 1.78
MNK's ROA % is ranked lower than
61% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. MNK: 1.78 )
Ranked among companies with meaningful ROA % only.
MNK' s ROA % Range Over the Past 10 Years
Min: -3.91  Med: 2.77 Max: 4.04
Current: 1.78
-3.91
4.04
ROC (Joel Greenblatt) % 19.45
MNK's ROC (Joel Greenblatt) % is ranked higher than
60% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. MNK: 19.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MNK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.34  Med: 18.27 Max: 50.3
Current: 19.45
3.34
50.3
3-Year Revenue Growth Rate 0.80
MNK's 3-Year Revenue Growth Rate is ranked lower than
67% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. MNK: 0.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MNK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -11.2  Med: -10.1 Max: 0.8
Current: 0.8
-11.2
0.8
3-Year EBITDA Growth Rate 51.90
MNK's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. MNK: 51.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MNK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.5  Med: 11.5 Max: 51.9
Current: 51.9
-7.5
51.9
GuruFocus has detected 2 Warning Signs with Mallinckrodt PLC $MNK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MNK's 10-Y Financials

Financials (Next Earnings Date: 2017-05-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MNK Guru Trades in Q1 2016

Joel Greenblatt 580,887 sh (New)
David Dreman 4,027 sh (+1883.74%)
Ken Heebner 1,125,000 sh (+69.17%)
John Paulson 8,949,380 sh (+3.78%)
First Eagle Investment 187 sh (unchged)
Louis Moore Bacon Sold Out
Jeremy Grantham Sold Out
George Soros Sold Out
Paul Tudor Jones 7,622 sh (-5.87%)
Mario Gabelli 14,562 sh (-6.43%)
» More
Q2 2016

MNK Guru Trades in Q2 2016

Steven Cohen 120,400 sh (New)
David Dreman 4,448 sh (+10.45%)
First Eagle Investment 187 sh (unchged)
Mario Gabelli 14,562 sh (unchged)
John Paulson 8,371,080 sh (-6.46%)
Ken Heebner 1,014,000 sh (-9.87%)
Paul Tudor Jones 5,434 sh (-28.71%)
Joel Greenblatt 246,825 sh (-57.51%)
» More
Q3 2016

MNK Guru Trades in Q3 2016

Jim Simons 207,102 sh (New)
Paul Tudor Jones 7,336 sh (+35.00%)
Joel Greenblatt 327,572 sh (+32.71%)
First Eagle Investment 187 sh (unchged)
David Dreman 4,448 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 14,462 sh (-0.69%)
John Paulson 7,974,472 sh (-4.74%)
Ken Heebner 880,500 sh (-13.17%)
» More
Q4 2016

MNK Guru Trades in Q4 2016

Steven Cohen 120,900 sh (New)
Paul Tudor Jones 19,556 sh (+166.58%)
Mario Gabelli 17,425 sh (+20.49%)
John Paulson 7,976,872 sh (+0.03%)
First Eagle Investment 187 sh (unchged)
Joel Greenblatt Sold Out
Ken Heebner Sold Out
Jim Simons Sold Out
David Dreman 84 sh (-98.11%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:VRX » details
Traded in other countries:MCD.Germany,
Mallinckrodt PLC along with its subsidiaries operates in a specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents.

Mallinckrodt is a specialty pharmaceutical company that was spun off from Covidien. The company has two segments in branded pharmaceuticals and generic drugs following the sale of its nuclear imaging business in 2016. Branded drugs make up approximately 70% of revenue. The firm's generic drug segment focuses primarily on products in the pain therapeutic area.

Ratios

vs
industry
vs
history
PE Ratio 17.94
MNK's PE Ratio is ranked higher than
75% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.26 vs. MNK: 17.94 )
Ranked among companies with meaningful PE Ratio only.
MNK' s PE Ratio Range Over the Past 10 Years
Min: 9.46  Med: 23.79 Max: 73.31
Current: 17.94
9.46
73.31
Forward PE Ratio 6.05
MNK's Forward PE Ratio is ranked higher than
97% of the 109 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.08 vs. MNK: 6.05 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 25.75
MNK's PE Ratio without NRI is ranked higher than
56% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.28 vs. MNK: 25.75 )
Ranked among companies with meaningful PE Ratio without NRI only.
MNK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.7  Med: 45.9 Max: 3311.75
Current: 25.75
12.7
3311.75
Price-to-Owner-Earnings 8.14
MNK's Price-to-Owner-Earnings is ranked higher than
93% of the 302 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.92 vs. MNK: 8.14 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MNK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.82  Med: 9.12 Max: 9.93
Current: 8.14
7.82
9.93
PB Ratio 0.95
MNK's PB Ratio is ranked higher than
92% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. MNK: 0.95 )
Ranked among companies with meaningful PB Ratio only.
MNK' s PB Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.06 Max: 3.59
Current: 0.95
0.9
3.59
PS Ratio 1.49
MNK's PS Ratio is ranked higher than
74% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. MNK: 1.49 )
Ranked among companies with meaningful PS Ratio only.
MNK' s PS Ratio Range Over the Past 10 Years
Min: 1.11  Med: 2.44 Max: 6.47
Current: 1.49
1.11
6.47
Price-to-Free-Cash-Flow 5.66
MNK's Price-to-Free-Cash-Flow is ranked higher than
93% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.25 vs. MNK: 5.66 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MNK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.44  Med: 16.31 Max: 2102.65
Current: 5.66
5.44
2102.65
Price-to-Operating-Cash-Flow 4.59
MNK's Price-to-Operating-Cash-Flow is ranked higher than
91% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.28 vs. MNK: 4.59 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MNK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.42  Med: 13.71 Max: 45.78
Current: 4.59
4.42
45.78
EV-to-EBIT 45.81
MNK's EV-to-EBIT is ranked lower than
85% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.12 vs. MNK: 45.81 )
Ranked among companies with meaningful EV-to-EBIT only.
MNK' s EV-to-EBIT Range Over the Past 10 Years
Min: 19.7  Med: 45.1 Max: 192.1
Current: 45.81
19.7
192.1
EV-to-EBITDA 9.90
MNK's EV-to-EBITDA is ranked higher than
76% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.99 vs. MNK: 9.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.3  Med: 14.7 Max: 34
Current: 9.9
8.3
34
PEG Ratio 1.74
MNK's PEG Ratio is ranked higher than
55% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. MNK: 1.74 )
Ranked among companies with meaningful PEG Ratio only.
MNK' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.88
Current: 1.74
0
1.88
Current Ratio 1.20
MNK's Current Ratio is ranked lower than
81% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. MNK: 1.20 )
Ranked among companies with meaningful Current Ratio only.
MNK' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.29 Max: 2.86
Current: 1.2
1.2
2.86
Quick Ratio 0.93
MNK's Quick Ratio is ranked lower than
79% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. MNK: 0.93 )
Ranked among companies with meaningful Quick Ratio only.
MNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.64 Max: 2.41
Current: 0.93
0.93
2.41
Days Inventory 83.76
MNK's Days Inventory is ranked higher than
67% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. MNK: 83.76 )
Ranked among companies with meaningful Days Inventory only.
MNK' s Days Inventory Range Over the Past 10 Years
Min: 71.49  Med: 81.23 Max: 169.11
Current: 83.76
71.49
169.11
Days Sales Outstanding 47.73
MNK's Days Sales Outstanding is ranked higher than
76% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. MNK: 47.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.73  Med: 73.29 Max: 105.41
Current: 47.73
47.73
105.41
Days Payable 27.52
MNK's Days Payable is ranked lower than
87% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. MNK: 27.52 )
Ranked among companies with meaningful Days Payable only.
MNK' s Days Payable Range Over the Past 10 Years
Min: 26.34  Med: 41.19 Max: 52.77
Current: 27.52
26.34
52.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -22.90
MNK's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. MNK: -22.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.3  Med: -26.2 Max: -22.9
Current: -22.9
-26.3
-22.9

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.61
MNK's Price-to-Median-PS-Value is ranked higher than
89% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. MNK: 0.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MNK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 0.98 Max: 2.48
Current: 0.61
0.49
2.48
Earnings Yield (Greenblatt) % 2.18
MNK's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. MNK: 2.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 2.2 Max: 5.1
Current: 2.18
0.5
5.1

More Statistics

Revenue (TTM) (Mil) $3,296
EPS (TTM) $ 2.50
Beta1.80
Short Percentage of Float15.78%
52-Week Range $41.57 - 85.83
Shares Outstanding (Mil)104.69

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 3,304 3,404 3,494
EPS ($) 7.54 8.35 9.13
EPS without NRI ($) 7.54 8.35 9.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.00%
Dividends per Share ($)
» More Articles for MNK

Headlines

Articles On GuruFocus.com
David Einhorn Converses on Range of Topics, Stocks With New York Times Editor Oct 20 2016 
10 Stocks David Dreman Is Buying Sep 21 2016 
Swiss Generics Manufacturer Has Strong 1st Half of Year Aug 22 2016 
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
John Paulson Keeps Gold, Buys Drug Manufacturers Nov 17 2015 
Pioneer Investments Adds to Stakes in Hartford Financial Group, Reynolds American Nov 13 2015 
Andreas Halvorsen Buys AIG, Google, 3 More as Top New Stocks May 29 2015 
Only Buy Luxury At A Deep Discount Apr 01 2015 
Mallinckrodt Has Brighter Days Going Ahead Mar 10 2015 

More From Other Websites
MALLINCKRODT 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney... Mar 24 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Mar 24 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against... Mar 24 2017
MNK DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Mar 24 2017
March 27 Deadline Alert: Law Offices of Howard G. Smith Reminds Mallinckrodt Public Limited Company... Mar 24 2017
Mallinckrodt plc To Report Earnings Results For First Quarter Of Fiscal 2017 Mar 24 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 23 2017
Sears, Nike and US Bancorp stumble while FedEx, Duluth rise Mar 22 2017
Something weird's going on with the doctors prescribing one of pharma's most controversial... Mar 21 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Mar 20 2017
Mallinckrodt Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For... Mar 20 2017
EXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover... Mar 17 2017
UPDATE: Hagens Berman Alerts Mallinckrodt Investors to the Expanded Class Period and Reminds them of... Mar 15 2017
MALLINCKRODT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC... Mar 13 2017
Short-seller Left on Intel-Mobileye: Didn't expect whatso... Mar 13 2017
MNK SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Mar 13 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 13 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors who Suffered Losses in Excess of... Mar 12 2017
MALLINCKRODT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS... Mar 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)